News

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/